Laborie Medical Technologies, a provider of diagnostic and therapeutic products, has acquired US-based medical device company Pelvalon for an undisclosed sum.
Based in Redwood City of California, Pelvalon is focused on the development of better treatments for female pelvic and bowel health.
Pelvalon has developed a non-surgical patient-controlled device called the Eclipse system to treat women suffering from faecal incontinence (FI), a pelvic floor disorder that is said to affect one in ten women.
Pelvalon founder and CEO Miles Rosen said: “I am grateful for the dedicated work of my colleagues to bring the therapy to this point, and we are delighted that Laborie will be able to scale and deliver Eclipse™ to the doctors and patients who need it.”
Eclipse is claimed to be the first vaginal insert designed to provide bowel control. It will be placed in the same location as a tampon or a diaphragm, and also can be inserted or removed at any time.
A detachable and discreet pump will be used to inflate and deflate a balloon on the insert. The balloon will help control and prevent stool from passing when the person is not ready for it.
Laborie president and CEO Michael Frazzette said: “Laborie’s mission every day is to operate as a world-class specialist medical company making and advancing technologies that preserve and restore human dignity.
“Our mission is well served by the addition of Eclipse™ to help patients who suffer from this difficult condition.”
Pelvalon founder and CEO Miles Rosen said: “I am grateful for the dedicated work of my colleagues to bring the therapy to this point, and we are delighted that Laborie will be able to scale and deliver Eclipse to the doctors and patients who need it.”
In March 2018, Laborie Medical agreed to acquire Cogentix Medical, which is engaged in the designing, development, manufacturing and marketing of flexible endoscopy products.
